Updated safety analysis

2023

General Safety
Infections
Malignancies
Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and progressive multiple sclerosis
Data-cut: November 2022
View ECTRIMS 2023 presentation (512kb)

Pregnancy
Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis: Analysis of the largest available outcomes database
Data-cut: July 2023
View ECTRIMS 2023 presentation (386kb)

2022

General Safety
Infections
Malignancies
Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis
Data-cut: November 2021
View ECTRIMS 2022 presentation (325kb)

COVID-19
COVID-19 in people with multiple sclerosis treated with ocrelizumab: Clinical outcomes in vaccinated patients
Data-cut: May 2021
View ECTRIMS 2022 presentation (342kb)

IRRs
Infusion-Related Reactions With Ocrelizumab in Relapsing Multiple Sclerosis: Over 9 Years of Data From OPERA OLE
Data-cut: November 2021
View ECTRIMS 2022 presentation (291kb)

Pregnancy
Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab
Data-cut: March 2022
View ECTRIMS 2022 presentation (856kb)

Pregnancy
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants
Publication date: August 2022
View full manuscript (0kb)

Infections
Risk factors for serious infections in patients with MS receiving long-term ocrelizumab treatment: Multivariate analyses
Data-cut: January 2020
View EAN 2022 presentation (362kb)

2021

COVID-19
Understanding the impacts of the COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
Publication date: October 2021
View full manuscript (0kb)
General Safety
IRRs
Infections
Malignancies
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Data-cut: January 2020
View full manuscript (0kb)

2020

COVID-19
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Data-cut: July 2020
View full manuscript (0kb)
                      
Vaccines
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study
Data-cut: February 2017
View full manuscript (0kb)
                      
                      
COVID-19
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series
Data-cut: April 2020
View full manuscript (0kb)

2019

PML
Cases reported as progressive multifocal leukoencephalopathy in ocrelizumab-treated patients with multiple sclerosis
Data-cut: July 2019
View ECTRIMS 2019 presentation (1086kb)

Abbreviations
COVID-19, coronavirus disease 2019; EAN, European Academy of Neurology; ECTRIMS, European Committee for Treatment and Research in MS; IRRs, infusion-related reactions; OLE, open-label extension; PML, progressive multifocal leukoencephalopathy.

M-XX-00015950 (Date of preparation: January 2024)

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.
Archived data reports for fatalities were last updated February 2021. Please note that there will be no further updates of these archived materials
Legal Statement
|
Privacy Policy
|
Sitemap
|
Cookies Settings
© F. Hoffmann La-Roche Ltd. |
This site is intended for healthcare professionals only, outside the US.
M-XX-00016074 (Date of preparation: January 2024)

To request a copy of your local ocrelizumab prescribing information, please click here